8-K: Shuttle Pharmaceuticals Faces Nasdaq Noncompliance Over Delayed Filing

Shuttle Pharmaceuticals Holdings, Inc. has received a notification from Nasdaq regarding non-compliance with listing rules due to a delayed Form 10-Q filing, with a deadline to submit a compliance plan.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. received a notification from Nasdaq on August 28, 2026, stating it is not in compliance with continued listing requirements.
• The non-compliance stems from the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2026.
• The company has until October 27, 2026, to submit a plan to regain compliance.
• If Nasdaq accepts the plan, the company may receive an extension up to February 22, 2027, to file the report.
• Failure to regain compliance could lead to the delisting of the company's common stock from Nasdaq.
• The company is actively working to complete and file the Form 10-Q as soon as possible.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the non-compliance with Nasdaq listing rules and the potential for delisting, despite the company's efforts to rectify the situation.

Positives

• The company is actively working to complete and file the delayed Form 10-Q as soon as practicable.
• Nasdaq has provided a defined period (60 days) to submit a plan for regaining compliance.
• If a plan is accepted, an extension of up to 180 days from the original due date is possible, providing a runway until February 22, 2027.

Negatives

• The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1).
• The delayed filing of the Form 10-Q for the period ended June 30, 2026, triggered the non-compliance notice.
• There is no assurance that Nasdaq will accept the company's plan to regain compliance.
• There is no assurance that the company will be able to regain compliance within any extension period granted.
• Nasdaq will broadcast an indicator noting the company's noncompliance, which may affect investor perception.
• If compliance is not regained, the company's common stock is subject to delisting from Nasdaq.

Risks

• The primary risk is the potential delisting of Shuttle Pharmaceuticals' common stock from The Nasdaq Stock Market LLC if compliance with listing rules is not regained.
• There is a risk that Nasdaq may not accept the company's plan to regain compliance.
• There is a risk that the company may not be able to regain compliance within the extended period granted by Nasdaq.
• Factors that could cause differences in forward-looking statements include the timing and results of the completion of required procedures by the independent registered public accounting firm and the company's ability to file the Form 10-Q.

Future Outlook

The company is focused on completing and filing its Form 10-Q as soon as practicable and submitting a plan to Nasdaq to regain compliance with listing rules. The outcome of this process and the ability to regain compliance within the specified timelines remain uncertain.

Management Comments

• The Company continues to work diligently to complete the Form 10-Q and intends to file the Form 10-Q as soon as practicable.
• The Company is required to submit a plan, by October 27, 2026, which outlines the steps the Company expects to take to regain compliance.

Industry Context

StockSavvy.ai notes that timely and accurate financial reporting is a fundamental requirement for listed companies. Delays in filing can erode investor confidence and lead to regulatory scrutiny, as demonstrated by this Nasdaq notification. For pharmaceutical companies, especially those in early-stage development, maintaining listing compliance is crucial for access to capital markets.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to non-compliance and risk of delisting; uncertainty regarding the company's ability to regain compliance.
• Creditors: Potential increased risk if delisting impacts the company's ability to access capital or maintain operations.
• Employees: Potential impact on morale and job security if delisting or continued non-compliance affects the company's stability.

Next Steps

• Submit a plan to Nasdaq by October 27, 2026, outlining steps to regain compliance.
• Complete and file the Quarterly Report on Form 10-Q for the period ended June 30, 2026, as soon as practicable.
• Work with independent registered public accounting firm to complete required procedures and documentation for the Form 10-Q review.

Key Dates

Recommendation

The filing indicates a significant risk of delisting due to delayed filings, which is a serious concern. However, the company is actively working to resolve the issue and has a defined path to potentially regain compliance. A 'hold' recommendation reflects the uncertainty and risk, while acknowledging the company's stated efforts to rectify the situation. Investors should monitor the progress of the compliance plan submission and Nasdaq's response.

Keywords

Nasdaq noncompliance, delayed filing, Form 10-Q, listing rules, delisting risk, compliance plan, pharmaceuticals